<DOC>
	<DOC>NCT01035385</DOC>
	<brief_summary>This study is a multicenter, open-label, randomized ,controlled phase III study to compare preoperative and postoperative with FOFLOX4 chemotherapy and postoperative with FOFLOX4 chemotherapy in patients with resectable liver metastasis from colorectal cancer.</brief_summary>
	<brief_title>Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)</brief_title>
	<detailed_description>To investigate the three-year progression free survival (PFS) advantage of FOLFOX4 in the treatment of resectable metastatic colorectal cancer.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1. Resectable liver metastasis from colorectal cancer(the distance from the tumor lower edge to anal more than 12cm),no visible extrahepatic metastatic tumors. Curable by resection, as determined by a surgeon and imaging physicians. The minimum of the liver metastases needs ≥2cm. Patients can be recruited if meet the conditions about: Primary tumor had been removed of the metachronous liver metastasis patients and no residue from the eyes or microscope. Primary tumor has been removed more than 1 month of the simultaneous liver metastasis patients. 2. Age of≥18 and ≤80 3. ECOG≤2 4. Signed written informed consent 1. Peripheral neuropathy(CTC＞1) 2. Had a neurological or mental disorders 3. Active infection 4. Allergy to Platinumbased and other drugs 5. Other acute diseases including infection, heartdisease(CHF, stable or unstable angina) 6. Pregnant or nursing patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>FOFLOX4</keyword>
	<keyword>resectable liver metastasis from colorectal cancer</keyword>
</DOC>